Considering the huge therapeutic importance of immune checkpoint inhibitors targeting the PD-1/PD-L1 interaction, it is worth mentioning that such interaction is modulated by glycosylation and that glycosylation inhibitors are able to revert the cancer-induced inhibition of the immune system [65,119,120,121,122,123,124]. Here, CD274 is linked to cancer.